Targeting PI3K/AKT pathway in triple-negative breast cancer

Affiliations

¹ Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France. Electronic address: Suzette.delaloge@gustaveroussy.fr.
² Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France.

Comment

Suzette Delaloge et al. Lancet Oncol. 2017 Oct.

. 2017 Oct;18(10):1293-1294.

doi: 10.1016/S1470-2045(17)30514-4. Epub 2017 Aug 8.

¹ Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France. Electronic address: Suzette.delaloge@gustaveroussy.fr.
² Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France.

No abstract available

Comment in

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS.
Kim SB, Dent R, Wongchenko MJ, Singel SM, Baselga J; LOTUS investigators. Kim SB, et al. Lancet Oncol. 2017 Nov;18(11):e638. doi: 10.1016/S1470-2045(17)30785-4. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208392 No abstract available.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Kim SB, et al. Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8. Lancet Oncol. 2017. PMID: 28800861 Free PMC article. Clinical Trial.